Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FGF1T2D

Financiado

Cerrado

FGF1 a novel metabolic regulator involved in insulin sensitization and glycemic...

FGF1 a novel metabolic regulator involved in insulin sensitization and glycemic control Type 2 diabetes (T2D) and obesity are leading causes of mortality and are associated with the Western lifestyle, which is characterized by excessive nutritional intake and lack of exercise. A central player in the pathophysiology... ver más

31/07/2015

UNIVERSITAIR MEDIS...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-07-31 No tenemos la información de la convocatoria

0% 100% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITAIR MEDISCH CENTRUM...

0.00€ | Lider

Proyectos interesantes

ALK7

Medical Technol...

Data Science

2M€ Cerrado

ICEBERG

Medical Technol...

Data Science

3M€ Cerrado

SiCMetabol

Medical Technol...

Data Science

1M€ Cerrado

Multi-Islet

Medical Technol...

Data Science

200K€ Cerrado

INSIGHT

Medical Technol...

Data Science

2M€ Cerrado

BetaRegeneration

Medical Technol...

Data Science

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

ACADEMISCH ZIEKENHUIS GRONINGEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Type 2 diabetes (T2D) and obesity are leading causes of mortality and are associated with the Western lifestyle, which is characterized by excessive nutritional intake and lack of exercise. A central player in the pathophysiology of these diseases is the nuclear hormone receptor (NHR) PPARγ, a lipid sensor and master regulator of adipogenesis. PPARγ is also the molecular target for the Thiazolidinedione (TZD)-class of insulin sensitizers, which command a large share of the current oral anti-diabetic drug market. Despite their efficacy in glycemic control, TZDs are associated with various adverse side effects, including weight gain, edema, and liver and cardiovascular toxicity, which limits their clinical use. During my postdoctoral research in the laboratory of dr Ronald M. Evans, at The Salk Institute, I have developed a novel screening tool for the functional analysis of complex transcriptional pathways. Using this technology, we have identified Fibroblast Growth Factor 1 (FGF1) as a novel target of PPARγ. In experiments with FGF1 knockout mice, we further demonstrated that these mice develop high-fat diet induced insulin resistance and hepatic steatosis, underscoring its significance in the development of T2DM. The studies proposed here aim to investigate the pharmacologic effects of FGF1 on energy metabolism and the development of T2D. This novel pathway defines a previously unrecognized mechanism for the insulin sensititizing actions of TZDs. Therapeutic targeting of FGF1 could serve as an improved strategy for the treatment of T2D, eliminating some of the adverse effects of TZDs that are mediated through direct activation of PPARγ.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores